Stocks
Stoke Therapeutics, Inc.STOK
NASDAQHealthcareBiotechnology$25.04
Price as of · delayed, not real-time
A clinical-stage biotechnology company developing antisense oligonucleotide therapies to restore protein production for genetic diseases, with a lead program targeting Dravet syndrome. Investors track it for its potential to address the root cause of severe neurological disorders and for upcoming clinical data readouts.
52W Range: $20.32-$40.22
Congressional Interest in Stoke Therapeutics, Inc. (STOK)
No congressional trades have been disclosed for Stoke Therapeutics, Inc. (STOK) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading STOK?
No congressional trades found for this stock.